By convening innovative researchers across academia, Brown’s new Center for Alzheimer’s Disease Research hopes to accelerate the pace of development for treatments and cures of this devastating disease.

Dr. Stephen Salloway, associate director of Brown’s new Center for Alzheimer’s Research who led clinical trials for the recently approved aducanumab, explained the key takeaways from the FDA’s headline-making decision.

New studies seek to get ahead of Alzheimer’s disease.

By bringing together biomedical research and discovery with world-class physician-scientists advancing care for patients with Alzheimer’s, the center aims to accelerate the pace of development for novel treatments and cures.

With $30 million in support, Brown launches Center for Alzheimer’s Disease Research

New studies seek to get ahead of Alzheimer’s disease.

By 2040, approximately one in five people in the U.S. will be 65 years old or older. As Americans are increasingly dealing with age-related diseases such as diabetes, heart disease, stroke, and Alzheimer’s, Brown researchers are trying to understand why aging occurs in an attempt to meet the country’s growing health care needs.

Deadly diseases don’t wait. Neither should good ideas. So when two undergraduates thought they’d found a way to stop neurodegeneration, they took action.